Additional funding for research and development costs incurred

No definition available.

Name:	adxn_AdditionalFundingForResearchAndDevelopmentCostsIncurred
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contract funding for research and development costs incurred

+ References

No definition available.

+ Details

Name:	adxn_ContractFundingForResearchAndDevelopmentCostsIncurred
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Increment period for extension of research term

+ References

No definition available.

+ Details

Name:	adxn_IncrementPeriodForExtensionOfResearchTerm
Namespace Prefix:	adxn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial research term

+ References

No definition available.

+ Details

Name:	adxn_InitialResearchTerm
Namespace Prefix:	adxn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of distinct material promises and performance obligations

+ References

No definition available.

+ Details

Name:	adxn_NumberOfDistinctMaterialPromisesAndPerformanceObligations
Namespace Prefix:	adxn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of newly identified compounds selected

+ References

No definition available.

+ Details

Name:	adxn_NumberOfNewlyIdentifiedComponentsSelected
Namespace Prefix:	adxn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Research funding paid by investor to third parties

+ References

No definition available.

+ Details

Name:	adxn_ResearchFundingPaidByInvestorToThirdParties
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research funding received

+ References

No definition available.

+ Details

Name:	adxn_ResearchFundingReceived
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Variable consideration allocated to contract

+ References

No definition available.

+ Details

Name:	adxn_VariableConsiderationAllocatedToContract
Namespace Prefix:	adxn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2024-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2024-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	ifrs-full_CounterpartiesAxis=adxn_IndiviorPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_RightsGrantedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_AchievementOfPreSpecifiedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_IfrsResearchMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=adxn_IndiviorPlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_CounterpartiesAxis=adxn_JanssenPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=adxn_DevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue from contract with customer (Details) € in Millions, $ in Millions						1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended		15 Months Ended
	Jul. 01, 2023 CHF (SFr)	Nov. 01, 2022 CHF (SFr)	May 01, 2021 CHF (SFr)	Oct. 30, 2020 USD ($)	Jan. 02, 2018 USD ($) item	Aug. 31, 2022 CHF (SFr)	Jan. 31, 2018 USD ($)	Jun. 30, 2025 CHF (SFr)	Jun. 30, 2024 CHF (SFr)	Jun. 30, 2025 CHF (SFr)	Jun. 30, 2024 CHF (SFr)	Jun. 30, 2024 CHF (SFr)	Dec. 31, 2019 USD ($)	Jul. 31, 2022 CHF (SFr)	Dec. 31, 2004 EUR (€)
Revenue from contract with customer
Revenue from contract with customer									SFr 115,277		SFr 348,757
Indivior PLC
Revenue from contract with customer
Number of distinct material promises and performance obligations \| item					2
Indivior PLC \| Rights granted
Revenue from contract with customer
Revenue from contract with customer \| $							$ 5.0
Indivior PLC \| Achievement of pre-specified milestones
Revenue from contract with customer
Variable consideration allocated to contract \| $					$ 330.0
Indivior PLC \| Research
Revenue from contract with customer
Revenue from contract with customer								SFr 0	SFr 100,000	SFr 0	300,000
Initial research term					2 years
Contract funding for research and development costs incurred \| $					$ 4.0
Increment period for extension of research term					12 months
Number of newly identified compounds selected \| item					1
Additional funding for research and development costs incurred	SFr 2,700,000	SFr 950,000	SFr 3,700,000	$ 2.8		SFr 850,000							$ 1.6
Research funding received												SFr 1,100,000		SFr 2,700,000
Research funding paid by investor to third parties												SFr 1,600,000		SFr 1,000,000
Indivior PLC \| Research \| Indivior PLC
Revenue from contract with customer
Number of newly identified compounds selected \| item					1
Janssen Pharmaceuticals Inc. \| Development
Revenue from contract with customer
Revenue from contract with customer										SFr 0	SFr 0
Janssen Pharmaceuticals Inc. \| Development \| Maximum
Revenue from contract with customer
Variable consideration allocated to contract \| €															€ 109